Both cell migration and invasion in the PC3 KO group were inhibited by the treatments, indicating that miR‐3934‐5p could counteract the efficacy of EGFR‐induced higher cancer cell motility (Fig. 3E‐H). This evidence concerns the gene EGFR and cancer.